Predictive factors for poor peripheral blood stem cell mobilization and peak CD34⁺cell count to guide pre-emptive or immediate rescue mobilization

References

• To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997; 89:2233–58.
   PubMed Web of Science ®Google Scholar
• Jillella AP, Ustun C. What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? Stem Cells Dev. 2004;13:598–606.
   PubMed Web of Science ®Google Scholar
• Vose JM, Ho AD, Coiffier B, Corradini P, Khouri I, Sureda A, . Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma. 2009; 50:1412–21.
   PubMed Web of Science ®Google Scholar
• Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, . Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet. 1992;339:640–4.
   PubMed Web of Science ®Google Scholar
• To LB, Roberts MM, Haylock DN, Dyson PG, Branford AL, Thorp D, . Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 1992;9:277–84.
   PubMed Web of Science ®Google Scholar
• Reiffers J, Faberes C, Boiron JM, Marit G, Foures C, Ferrer AM, . Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment. J Hematother. 1994;3:185–91.
   PubMedGoogle Scholar
• Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, . An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961–9.
   PubMed Web of Science ®Google Scholar
• Beguin Y, Baudoux E, Sautois B, Fraipont V, Schaaf-Lafontaine N, Pereira M, . Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34 + cells or unmanipulated peripheral blood stem and progenitors cells. Transfusion. 1998;38:199–208.
   Google Scholar
• Bolwell BJ, Pohlman B, Rybicki L, Sobecks R, Dean R, Curtis J, . Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 2007;40:437–41.
   PubMed Web of Science ®Google Scholar
• To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118: 4530–40.
   PubMed Web of Science ®Google Scholar
• Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, . Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14:1045–56.
   PubMed Web of Science ®Google Scholar
• Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, . Poor mobilization of hematopoietic stem cells. Definitions, incidence, risk factors and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant. 2010;16:490–9.
   PubMed Web of Science ®Google Scholar
• Sancho JM, Ribera JM, Oriol A, Batlle M, Flores A, Rodríguez LL, . Causas por las que no se realiza el trasplante de progenitores hematopoyéticos en pacientes remitidos a una unidad de trasplante. Med Clin (Barc). 2003;121:401–4.
   Google Scholar
• Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, . Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood. 1994;83: 3787–94.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, . 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113: 5720–6.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, . 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:4767–73.
   PubMed Web of Science ®Google Scholar
• Basak GW, Jaksic O, Koristek Z, Mikala G, Basic-Kinda S, Mayer J. Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. Eur J Haematol. 2011; 86:488–95.
   PubMed Web of Science ®Google Scholar
• Hübel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH, . European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant. 2011. doi:10.1038/bmt. 2011.216.
   Google Scholar
• Horwitz ME, Chute JP, Gasparetto C, Long GD, McDonald C, Morris A, . Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplant. 2011. doi:10.1038/bmt. 2011.217.
   Google Scholar
• Abhyankar S, Dejarnette S, Aljitawi O, Ganguly S, Merkel D, McGuirk J. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with use of plerixafor. Bone Marrow Transplant. 2012;47:483–487.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Lemoli RM. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion. 2012;52:906–914.
   PubMed Web of Science ®Google Scholar
• Sutherland R, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+cell determination by flow cytometry. Hematotherapy J. 1996;5:213–26.
   PubMedGoogle Scholar
• Perez-Simon JA, Caballero MD, Corral M, Nieto MJ, Orfao A, Vazquez L, . Minimal number of circulating CD34+cells to ensure success leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion. 1998;38:385–91.
   PubMed Web of Science ®Google Scholar
• Kuittinen T, Nousiainen T, Halonen P, Mahlamaki E, Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2004; 33:907–12.
   PubMed Web of Science ®Google Scholar
• Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, . Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol. 2009; 84:335–7.
   PubMed Web of Science ®Google Scholar
• Duong HK, Bolwell BJ, Rybicki L, Koo A, His ED, Figueroa P, . Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+cell yield. J Clin Apher. 2011;26: 111–15.
   PubMed Web of Science ®Google Scholar
• Koenigsmann M, Jentsch-Ullrich K, Mohren M, Becker E, Heim M, Franke A. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion. 2004;44:777–84.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Apostolidis J, Rohatiner AZ, Wiggins C, Crawley CR, Foron JM, . Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J. 2000;1:367–73.
   PubMedGoogle Scholar
• Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008;322:1861–5.
   PubMed Web of Science ®Google Scholar
• Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, . Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011;121:1298–312.
   PubMed Web of Science ®Google Scholar
• Tournilhac O, Cazin B, Lepètre S, Diviné M, Maloum K, Delmer A, . Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 2004;103:363–5.
   PubMed Web of Science ®Google Scholar
• Berger MG, Berger J, Richard C, Jeanpierre S, Nicolini FE, Tournilhac O, . Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggest impaired bone marrow niche and HP mobilization. Leukemia. 2008;22:2131–4.
   PubMed Web of Science ®Google Scholar
• Waterman J, Rybicki L, Bolwell B, Copelan E, Pohlman B, Sweetenham J, . Fludarabine as a risk factor for poor stem cell harvest, treatment-realted MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47: 488–493.
   PubMed Web of Science ®Google Scholar
• Clark RE, Brammer CG. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant. 1998;22:859–69.
   PubMed Web of Science ®Google Scholar
• Stiff PJ. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant. 1999;23 (Suppl 2):S29–33.
   Google Scholar
• Basak GW, Jaksic O, Koristek Z, Mikala G, Mayer J, Masszi T, . Central and Eastern European Leukemia Group (CELG). Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. Am J Hematol. 2011;86:550–3.
   PubMed Web of Science ®Google Scholar
• Sagüés M, Sancho JM, Serrano D, Balsalobre P, Gayoso J, Morgades M, . Comparison of two initial mobilizing strategies of peripheral blood stem cells for autologous transplantation in patients with lymphoma and human immunodeficiency virus infection. Med Clin (Barc). 2011. Epub ahead of print.
   Google Scholar
• Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, . A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+peripheral blood progenitor cells in normal donors. Br J Haematol. 2000;109:770–2.
   PubMed Web of Science ®Google Scholar
• Szwajcer D, Jennings-Coutts A, Giftakis A, Wall DA. Identification of the CD34 enumeration on the day before stem cell harvest that best predicts poor mobilization. Transfusion. 2011;51:587–90.
   Google Scholar
• Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F, . Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant. 2011;46: 943–9.
   PubMed Web of Science ®Google Scholar